Dialysis Without Compromise

Osman founded Diality in 2018, the culmination of his extensive experience as a physician entrepreneur. He is a board-certified nephrologist with a passion for home dialysis stemming from years running several dialysis units in the San Diego area. Osman obtained his MD from the University of Glasgow and his MPH from Johns Hopkins University.

A 20-year veteran of the medical device and pharmaceutical industries, Dan most recently was Chief Commercial Officer for Neuronetics where after a 2018 IPO he grew the commercial organization to secure market leadership within the category. Before Neuronetics, he held senior commercial roles at JADAK, Zimmer Biomet, Medtronic and Fleet Laboratories. Dan earned his bachelor's degree in finance and marketing from American University and his MBA from Southern Illinois University at Carbondale.

Peter brings 35 years of life sciences industry experience to Diality, including CFO roles with Impulse Dynamics and Zomedica. He led several successful corporate exits and IPOs, most notably Standard Bariatrics, Neuronetics, and Assurex Health. Prior to Assurex Health, Peter also held leadership roles with Bovie Medical and Cyberonics. Peter graduated magna cum laude from the Fisher College of Business at the Ohio State University-Columbus and earned his MBA from the University of Akron.

Jahnavi obtained her MS from Texas A&M and her MBA from UCLA. She is a very experienced product developer. She previously worked at Sparton, a contract manufacturing and design company, as General Manager of the Irvine office. There she oversaw a multitude of electromechanical and software medical devices and brings a depth of experience in medical devices.

Blaine brings more than 10 years of engineering leadership to Diality. He received his BS in Electrical Engineering from the University of Hawaii where he was nationally recognized for scholastic excellence. Prior to Diality, Blaine honed his passion for medical device product development in senior engineering roles with Becton Dickinson and Vyaire.

Clayton Poppe leads Research and Hardware Engineering at Diality, translating complex engineering challenges into innovative dialysis technologies that advance patient care. His experience includes developing the first home hemodialysis machine at Aksys Ltd. He holds a BS in Mechanical Engineering from Duke University and an MS in Systems Engineering and MBA from MIT.

Osman founded Diality in 2018, the culmination of his extensive experience as a physician entrepreneur. He is a board-certified nephrologist with a passion for home dialysis stemming from years running several dialysis units in the San Diego area. Osman obtained his MD from the University of Glasgow and his MPH from Johns Hopkins University.

Dr. Nissenson is Emeritus Professor of Medicine at the David Geffen School of Medicine at UCLA where he also served as both associate dean and the director of the dialysis program. He was Chief Medical Officer for DaVita Kidney Care for over 11 years. He is the past chair of Kidney Care Partners and past co-chair of the Kidney Care Quality Alliance. He has authored over 700 publications in nephrology, dialysis, anemia management, and health care delivery and policy.

Martin represents the largest shareholder and is a hands-on strategic advisor. Martin has extensive experience working with numerous firms in the Pharma, Chemical, and Med-tech industries. He served in roles including Global Business Head, CTO, and Chief Innovation Officer in the US and Europe. Martin is an alumnus of ETH Zurich, Princeton University, and Harvard University.

Robert has spent nearly 50 years in the healthcare industry in both services and medical devices and has a proven track record of delivering shareholder value. He served as president and CEO of Syncor International and Crescent Healthcare, and was chairman of NxStage Medical until its acquisition by Fresenius Medical Care. Prior to Syncor, Robert spent nearly 20 years in management with Baxter International. Robert is an alumnus of Harvard Business School and Cornell University.

Dr. Springer brings 30 years of biotech and pharmaceutical experience from his time with Vifor Pharma and Amgen. As Chief Strategy Officer for Vifor Pharma, he created a joint renal-drug company between Vifor Pharmaceuticals and Fresenius Medical Care and oversaw a series of licensing deals and acquisitions, culminating in CSL acquiring Vifor Pharma for $11.7B. Dr. Springer also sits on the board of several other biotech companies, including Adrenomed, Nagi Bioscience, Quercis Pharma, and HICT.